Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: Imaging in volunteers and patients with temporal lobe epilepsy

European Journal of Nuclear Medicine

Volumn 25, Issue 5, 1998, Pages 464-470

  Buck, Alfred ^a   Frey, Lukas D ^b   Bläuenstein, Peter ^c   Krämer, Günter ^d   Siegel, Adrian ^e   Weber, Bruno ^e   Schubiger, Pius A ^c   Wieser, Heinz G ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d SWISS EPILEPSY CENTER   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Monoamine oxidase B; Single photon emission tomography; Temporal lobe epilepsy

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; IODINE 123; MONOAMINE OXIDASE B INHIBITOR; RADIOPHARMACEUTICAL AGENT; RO 43 0463; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG UPTAKE; EQUIPMENT; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHOTON EMISSION TOMOGRAPHY; PUTAMEN; SCINTILLATION CAMERA; TEMPORAL LOBE; TEMPORAL LOBE EPILEPSY; VOLUNTEER;

ADULT; BRAIN; CASE-CONTROL STUDIES; EPILEPSY, TEMPORAL LOBE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PICOLINIC ACIDS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031799121     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050245     Document Type: Article

References (28)

1. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1969; 17: 1285-1297.
2. Glover V, Sandler M. Clinical chemistry of monoamine oxidase. Cell Biochem Funct 1986; 4: 89-97.
3. 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS. peripheral organs, and human brain. J Neurosci 1992; 12: 1977-1999.
4. Strolin-Benedetti M, Dostert P. Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 1989; 38: 555-561.
5. Oreland L, Gottfries CD. Brain monoamine oxidase in aging and in dementia of Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatr 1986; 10: 533-540.
6. Jossan SS, Gilberg PG, Karlsson I, Gottfries CD, Oreland L. Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study. J Neurotransm 1990; 32: 61-66.
7. Saura J, Luque JM, Cesura AM, et al., Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994; 62: 15-30.
8. Kumlin E. In vitro and in vivo studies on epileptogenic tissue in temporal lobe epilepsy. Acta Univ Upsaliensis 1994; n: 28-45.
9. Fowler JS, Volkow ND, Logan J, et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human MAO B inhibition by Ro 19-6327. Neurology 1993; 43: 1984-1992.
10. Bench CJ, Price GW, Lammertsma AA, et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991; 40: 169-173.
11. 123I N-(2-aminoethyl)-5-iodo-2-pyridinecarboxamide (Ro 43-0643), a monoamine oxidase B inhibitor. Nucl Med Biol 1991; 18: 563-564.
12. 123I-labelled MAO-B inhibitor. J Nucl Biol Med 1994; 38 (Suppl 1 to No. 4): 59-62.
13. 125I]-Ro 43-0463, a site specific tracer for MAO-B mapping with autoradiography as well as with SPET. J Recept Signal Transduction Res 1995; 15: 581-593.
14. 123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. Nucl Med Biol 1995; 22: 929-936.
15. 3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B. Eur J Pharmacol 1989; 162: 457-465.
16. 123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. Nucl Med Biol 1995; 22: 929-936.
17. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE NS 1978; 25: 638-639.
18. Talaraich J, Tournoux P. A co-planar stereotactic atlas of a human brain. Stuttgart: Thieme, 1988.
19. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994; 35: 2011-2018.
20. Frackowiak RS, Friston KJ. Functional neuroanatomy of the human brain: positron emission tomography - a new neuroanatomical technique. J Anat 1994; 184: 211-225.
21. 11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia 1995; 36: 712-721.
22. Fowler JS, Wang G, Logan J, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995; 36: 1255-1262.
23. 3H]deprenyl. Brain Res 1991; 547: 69-76.
24. 123I-labelled reversible inhibitors of monoamine oxidase B. Nucl Med Biol 1997; 25: 47-52.
25. Kotagal P, Luders H, Morris HH, et al. Dystonic posturing in complex partial seizures of temporal lobe onset: a new lateralizing sign [see comments]. Neurology 1989; 39 (2 Pt 1): 196-201.
26. Kotagal P, Luders HO, Williams G, Nichols TR, McPherson J. Psychomotor seizures of temporal lobe onset: analysis of symptom clusters and sequences. Epilepsy Res 1995; 20: 49-67.
27. Kotgagal P. Seizure symptomatology of temporal lobe origin. In: Lueders H, ed. Epilepsy surgery. New York: Raven Press; 1991: 143-155.
28. Mintun MA, Raichle ME, Kilbourn MR, Woolen GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-27.